Tumor Vasculature: A Target for Anticancer Therapies

Vascular-Targeted Therapies in Oncology

Volumn , Issue , 2006, Pages 1-8

  Siemann, Dietmar W ^a,b  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

Conventional treatment modalities; Increased tumor cell kill; Targeting tumor blood vessel network; Tumor endothelium; Tumor vasculature; Vascular targeting agents and conventional anticancer therapies; Vascular disrupting agents (VDAs); Vascular targeting therapies

Indexed keywords

EID: 84890638684     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/0470035439.ch1     Document Type: Chapter

References (43)

1. Arap, W., Pasqualini, R. and Ruoslahti, E. (1998). Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279, 377-380.
2. Ausprunk, D. and Folkman, J. (1977). Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis. Microvasc Res 14, 53-65.
3. Baguley, B.C. and Ching, L.M. (2002). DMXAA: an antivascular agent with multiple host responses. Int J Radiat Oncol Biol Phys 54, 1503-1511.
4. Blakey, D.C., Westwood, F.R., Walker, M., Hughes, G.D., Davis, P.D., Ashton, S.E. and Ryan, A.J. (2002). Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin Cancer Res 8, 1974-1983.
5. Bloemendal, H.J., Logtenberg, T. and Voest, E.E. (1999). New strategies in anti-vascular cancer therapy. Eur J Clin Invest 29, 802-809.
6. Brizel, D.M., Dodge, R.K., Clough, R.W. and Dewhirst, M.W. (1999). Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother Oncol 53, 113-117.
7. Brizel, D.M., Scully, S.P., Harrelson, J.M., Layfield, L.J., Bean, J.M., Prosnitz, L.R. and Dewhirst, M.W. (1996). Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 56, 941-943.
8. Brown, J.M. and Giaccia, A.J. (1998). The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 58, 1408-1416.
9. Chaplin, D.J. and Dougherty, G.J. (1999). Tumour vasculature as a target for cancer therapy. Br J Cancer 80, 57-64.
10. Chaplin, D.J., Pettit, G.R. and Hill, S.A. (1999). Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate. Anticancer Res 19, 189-195.
11. De Jaeger, K., Kavanagh, M.C. and Hill, R.P. (2001). Relationship of hypoxia to metastatic ability in rodent tumours. Br J Cancer 84, 1280-1285.
12. DeVita, V.T., Hellman, S. and Rosenberg, S. (1997). Cancer: Principles and Practice of Oncology. Lippincott-Raven, Philadelphia, PA.
13. Ellis, L.M., Liu, W., Ahmad, S.A., Fan, F., Jung, Y.D., Shaheen, R.M. and Reinmuth, N. (2001). Overview of angiogenesis: biologic implications for antiangiogenic therapy. Semin Oncol 28, 94-104.
14. Ellis, L.M., Takahashi, Y., Liu, W. and Shaheen, R.M. (2000). Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications. Oncologist 5 (SUPPL. 1), 11-15.
15. Fidler, I.J. and Ellis, L.M. (1994). The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 79, 185-188.
16. Folkman, J. (1986). How is blood vessel growth regulated in normal and neoplastic tissue? Cancer Res 46, 467-473.
17. Folkman, J. and Shing, Y. (1992). Angiogenesis. J Biol Chem 267, 10931-10934.
18. Giaccia, A.J. (1996). Hypoxic stress proteins: survival of the fittest. Semin Radiat Oncol 6, 46-58.
19. Graeber, T., Osmanian, C., Jacks, T., Housman, D., Koch, C.J., Lowe, S. and Giaccia, A.J. (1996). Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature 379, 88-91.
20. Hahnfeldt, P., Panigrahy, D., Folkman, J. and Hlatky, L. (1999). Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy. Cancer Res 59, 4770-4775.
21. Hill, R.P. (1990). Tumor progression: potential role of unstable genomic changes. Cancer and Metastasis Reviews 9, 137-147.
22. Hoeckel, M., Knoop, C., Schlenger, K., Vorndran, B., Baussman, E., Mitze, M., Knapstein, P.G. and Vaupel, P. (1993). Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol 26, 45-50.
23. Horsman, M.R. and Overgaard, J. (2002). The oxygen effect and the tumour microenvironment. In Basic Clinical Radiobiology for Radiation Oncologists, G.G. Steel (ed.). Arnold, London, pp. 158-168.
24. Kerbel, R.S. (2000). Tumor angiogenesis: past, present and the near future. Carcinogenesis 21, 505-515.
25. Konerding, M.A., Miodonski, A.J. and Lametschwandtner, A. (1995). Microvascular corrosion casting in the study of tumor vascularity: a review. Scanning Microsc 9, 1233-1244.
26. Konerding, M.A., van Ackern, C., Fait, E., Steinberg, F. and Streffer, C. (2002). Morphological aspects of tumor angiogenesis and microcirculation. In Blood Perfusion and Microenvironment of Human Tumors, M. Molls and P. Vaupel (eds). Springer, Berlin, pp. 5-17.
27. Nordsmark, M., Overgaard, M. and Overgaard, J. (1996). Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinioma of the head and neck. Radiother Oncol 41, 31-39.
28. O'Reilly, M.S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W.S., Flynn, E., Birkhead, J.R., Olsen, B.R. and Folkman, J. (1997). Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88, 277-285.
29. Ruoslahti, E. (2002). Specialization of tumour vasculature. Nat Rev Cancer 2, 83-90.
30. Schweigerer, L. (1995). Antiangiogenesis as a novel therapeutic concept in pediatric oncology. J Mol Med 73, 497-508.
31. Scott, P. and Harris, A.L. (1994). Current approaches to targeting cancer using antiangiogenesis therapies. Cancer Treat Rev 20, 393-412.
32. Siemann, D.W., Bibby, M.C., Dark, G.G., Dicker, A.P., Eskens, F.A.L.M., Horsman, M.R., Marme, D. and LoRusso, P.M. (2005). Differentiation and definition of vascular-targeted therapies. Clin Cancer Res 11, 416-420.
33. Siemann, D.W., Chaplin, D.J. and Horsman, M.R. (2004). Vascular-targeting therapies for treatment of malignant disease. Cancer 100, 2491-2499.
34. Siemann, D.W. and Shi, W. (2004). Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors. Int J Radiat Oncol Biol Phys 60, 1233-1240.
35. Steel, G.G. and Peckham, M.J. (1979). Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys 5, 85-91.
36. Strohmeyer, D. (1999). Pathophysiology of tumor angiogenesis and its relevance in renal cell cancer. Anticancer Res 19, 1557-1561.
37. Tannock, I.F. (1970). Population kinetics of carcinoma cells, capillary endothelial cells, and fibroblasts in a transplanted mouse mammary tumor. Cancer Res 30, 2470-2477.
38. Thorpe, P.E. (2004). Vascular targeting agents as cancer therapeutics. Clin Cancer Res 10, 415-427.
39. Twardowski, P. and Gradishar, W.J. (1997). Clinical trials of antiangiogenic agents. Curr Opin Oncol 9, 584-589.
40. Vaupel, P., Kallinowski, F. and Okunieff, P. (1989). Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 49, 6449-6465.
41. Vaupel, P., Thews, O. and Hoeckel, M. (1996). Tumor oxygenation: characterization and clinical implications. In rhErythropoietin in Cancer Supportive Treatment, J.F. Smyth, M.A. Boogaerts and B.R. Ehmer (eds). Dekker, pp. 205-239.
42. Wedge, S.R., Kendrew, J., Ogilvie, D.J., Hennequin, L.F., Brave, A.J., Ryan, A.J., Ashton, S.E., Calvete, J.A. and Blakey, D.C. (2002). Combination of the VEGF receptor tyrosine kinase inhibitor ZD6474 and vascular-targeting agent ZD6126 produces an enhanced anti-tumor response. Proc Am Assoc Cancer Res. 43, 1081 [abstract].
43. Young, S.D., Marshall, R.S. and Hill, R.P. (1988). Hypoxia induces DNA overreplication and enhances metastatic potential of murine tumor cells. Proc Natl Acad Sci 85, 9533-9537.